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Abstract: Chronic obstructive pulmonary disease (COPD) remains the fourth leading cause of 
death, is associated with significant morbidity and places a substantial time and cost burden on 
the health care system. Unfortunately, treatment for COPD remains underutilized and continues 
to focus on the acute care of complications. The chronic care model (CCM) shifts this focus 
from the acute management of symptoms and complications to the prevention and optimal 
management of the chronic disease. This model utilizes resources from the community and the 
health care system and emphasizes self-management, provides comprehensive clinic support, and 
implements evidence-based guidelines and technology into clinical practice to ensure delivery 
of the highest quality of care. The goal of this review is to use a case-based approach to provide 
practical information about how integrated care using the CCM can be applied to the clinical 
care of a complex patient with COPD, shifting the management goals for COPD from reactive 
to proactive and ultimately improving outcomes.
Keywords: lung disease, chronic obstructive integrated care, chronic care model, evidence-
based guidelines
Case history
Mrs B is a 56-year-old Caucasian woman who presents to establish care with a primary 
care clinician after relocating to the area. She reports a long history of tobacco use, 
hypertension, and gout. Her previous doctor had recently diagnosed her with chronic 
obstructive pulmonary disease (COPD) and started her on treatment with albuterol 
and ipratropium nebulizers after she complained of worsening dyspnea and cough.     
Mrs B, however, believes that these symptoms are primarily related to her   advancing 
age. Over the past year, she recalls three episodes of acute worsening of dyspnea 
in which one episode required hospitalization. On two of these occasions, she was 
forced to seek care at an urgent care facility because neither her primary clinician nor 
the clinic support staff could be reached in a timely manner for assistance. Her main 
concerns today are persistently cold hands over the past several months and worsen-
ing insomnia. The patient’s husband adds that lately it seems to take his wife twice 
as long to finish anything around the house and that she appears more withdrawn, 
excusing herself from activities outside the house. He also states that she often falls 
asleep during the day, even during her favorite television show. On exam, the patient 
is 5 feet, 8 inches tall, weighs 104 pounds, and has a resting room air oxygen satura-
tion of 82%. She appears thin with a rounded, barrel-shaped chest. Heart sounds are 
distant and breath sounds are diminished with occasional wheezing. Extremities appear Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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pale and are cool to palpation without evidence of clubbing. 
Chest radiograph shows hyperinflated lungs and osteopenic 
appearing ribs. Review of the patient’s past medical records 
shows a postbronchodilator forced expiratory volume in one 
second (FEV1) to forced vital capacity (FVC) ratio of 0.58 
(58%) and an FEV1 of 35% predicted.
Introduction
COPD is a preventable and treatable disease characterized 
by progressive airflow limitation that is not fully reversible.1 
Worldwide, COPD remains the leading cause of death from 
lung disease and the fourth leading cause of death overall.2 
In the United States alone, yearly data show that COPD is 
responsible for at least eight million outpatient clinician 
encounters, 1.5 million emergency department visits, and 
726,000 hospitalizations.3 Collectively, these hospitalizations 
  represent over 65% of COPD-related costs.4 Unfortunately, 
COPD remains underdiagnosed and undertreated in both its 
early and late stages and is associated with multiple comor-
bidities.3,5 Historically, the medical community has focused 
on acute care and short-term goals. Emphasis was placed on 
the management of acute exacerbations and complications 
and speeding time to recovery. This “acute care model” 
encouraged patients to assume a passive role in the manage-
ment of their disease and placed the bulk of responsibility for 
problem solving on the clinician. Unfortunately, this acute 
care model is broken and the Institute of Medicine reports that 
“the current care systems cannot do the job,” “trying harder 
will not work,” but “changing care systems will.”6
The Chronic Care Model
The Chronic Care Model (CCM) addresses these short-
comings by identifying essential elements that encourage 
high-quality chronic disease care.7–9 This model provides a 
multidisciplinary, organized approach to delivering care for 
patients with chronic diseases, which involves the commu-
nity and the health care system and fosters communication 
between clinicians and well-informed patients. The goals of 
this model are to (1) improve chronic disease management, 
(2) facilitate the prevention of complications, and (3) improve 
outcomes, including health care utilization and quality of life. 
With implementation of at least one CCM element, improved 
clinical outcomes were demonstrated in a meta-analysis of 
data on a variety of chronic diseases including asthma and 
congestive heart failure.10 In COPD, a significant benefit in 
outcomes was also seen if at least two CCM elements were 
present.11,12 Benefits identified by these systematic reviews 
included reductions in unscheduled clinic and emergency 
room visits, frequency of   hospitalizations, improved exercise 
capacity, and a shorter length of stay.
Components of the CCM include (1) self-management, 
(2) delivery system design, (3) decision support, and (4) clini-
cal information systems (http://www.  improvingchroniccare.
org). Self-management focuses on education to foster 
patient’s confidence and effort, thereby improving overall 
autonomy. This is accomplished not through lectures, but by 
using clinical scenarios in problem solving, skill develop-
ment, and decision making.13 Community-based resources 
are relied on heavily for this component, including pulmo-
nary rehabilitation programs, patient education materials, 
group classes, and ideally a home health case manager who 
can continuously assess difficulties as well as acknowledge 
accomplishments. A COPD “action plan” is probably the 
best known example of a self-management tool, but other 
effective interventions include medication compliance, 
proper inhaler technique, adequate nutrition, and regular 
exercise.14 To improve the quality of life in COPD patients, 
an “action plan” provides knowledge on COPD and its 
symptoms, suggests ways to control symptoms and maintain 
function, educates on the early recognition of acute exacerba-
tions of COPD (AECOPD), and plans for treatment using 
self-initiated prescriptions. It also promotes exercise, sleep, 
nutrition, and leisure to improve mental health.14 Therefore, 
self-management is an important component of the CCM.
The other components of the CCM include the delivery 
system design, clinical information systems, and decision 
support. Well-trained clinical teams to ensure successful self-
management, coordinate preventive care, screen for common 
comorbid diseases, and address questions or acute issues around 
the clock are the key features of delivery system design. An 
active clinical information system provides automated remind-
ers of practice guidelines as well as performance feedback to 
clinicians. Finally, the decision   support component involves the 
use of evidence-based practice guidelines, which are critical to 
optimally   managing any chronic illness. Effective management 
of complicated chronic diseases like COPD is best accomplished 
by   clinicians working in collaboration, not isolation, with the 
assistance of a variety of health care resources.
Diagnosing COPD
However, guidelines cannot be applied to patients who do 
not yet have a diagnosis of COPD. Therefore, identifying 
patients with the disease is important. Dyspnea and chronic 
cough are the cardinal features of COPD. Cough, which 
may be nonproductive, is often the first symptom of COPD, 
but is often overlooked by patients and may be intermittent Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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early in the disease course.15,16 There is typically a significant 
delay in the pursuit of medical care by patients with dysp-
nea, often waiting until symptoms affect the performance of 
activities of daily living. This reflects (1) the slow onset of 
COPD   symptoms that allows for gradual and compensatory 
  adjustments in lifestyle and (2) a tendency to subjectively 
minimize the degree of symptoms and/or redirect blame, 
most commonly attributing symptoms to advancing age. 
  Wheezing and chest tightness are nonspecific symptoms and 
their absence does not exclude the diagnosis of COPD.17
The diagnosis of COPD requires spirometry to con-
firm the presence of airflow obstruction in any patient 
presenting with symptoms and/or risk factors concerning 
for COPD.15   Airflow obstruction in COPD is defined as 
a   postbronchodilator FEV1 to FVC ratio of less than 0.70 
(70%).15 Severity of the disease is then based on the degree of 
reduction in the postbronchodilator FEV1, but can sometimes 
be inferred by severe symptoms and presence of associated 
complications. The Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines classify COPD as mild 
when the postbronchodilator FEV1 is greater than or equal 
to 80% predicted, moderate when 50% # FEV1 , 80% 
predicted, severe when 30% # FEV1 , 50% predicted, 
and very severe if FEV1 , 30% predicted or FEV1 , 50% 
predicted with the presence of chronic respiratory failure.6 
Interestingly, FEV1 does not consistently predict disability 
or mortality in COPD. A better predictor of morbidity and 
mortality from COPD is the BODE index, which includes the 
body mass index (B), the degree of airflow obstruction (O), 
dyspnea (D), and exercise capacity (E), assessed by the 
6-minute walk test.18
Asthma may be difficult to distinguish from COPD. 
Features that favor the diagnosis of asthma include largely 
reversible airflow limitation, significant daily variation in 
symptoms with a predominance of nocturnal or early morning 
symptoms, a family history of asthma, a history of   “childhood 
asthma,” age of onset of symptoms before 40 years old, 
minimal or no exposure to tobacco, and comorbid allergy 
or atopy.15 However, it is important to note that asthma can 
present in adulthood, some asthmatics smoke cigarettes, and 
asthma and COPD coexist in up to 10%–15% of patients; 
therefore, clinical judgment is necessary in defining patients 
with obstructive lung disease. Other diseases of airflow 
obstruction with dyspnea and cough include congestive 
heart failure, bronchiectasis, obliterative bronchiolitis, and a 
variety of pulmonary infections including tuberculosis. These 
alternative diagnoses are typically easily differentiated from 
COPD by history and imaging of the chest.
The leading risk factor for COPD remains cigarette 
  smoking.19 Other risk factors include second-hand smoke, 
occupational dusts and chemicals, and indoor air pollution 
from biomass cooking and heating in poorly ventilated 
areas.20–22 The role of outdoor air pollution in the etiology of 
COPD is unclear.15 The evidence-based GOLD guidelines 
emphasize that the most important and effective aspect of 
COPD management is smoking cessation.1,15 In an 11-year 
follow-up study, participants who continued to smoke 
saw an average yearly decline in FEV1 twice as great as 
  ex-smokers.23 In   addition, the rate of decline in lung   function 
in ex-smokers did not differ significantly from never-  smokers. 
A   significant reduction in symptoms of cough, sputum pro-
duction,   wheezing, and shortness of breath is also seen in 
patients with COPD who quit smoking.24 All patients with 
COPD who continue to smoke should, therefore, receive help 
with smoking cessation, including counseling and potentially 
pharmacotherapy to achieve smoking abstinence. In addition, 
ex-smokers should be congratulated and reminded of the 
importance of remaining tobacco free.
Evidence-based COPD treatment
The GOLD guidelines recommend that symptomatic patients 
with COPD should be treated with bronchodilators.15 Cur-
rent pharmacotherapy for COPD has been shown to decrease 
symptoms and complications, but does not help modify the 
clinical course including the decline in lung function or 
survival. In patients with mild COPD, short-acting bron-
chodilator therapy is recommended on an as-needed basis 
for relief of symptoms.15 Either a β2-agonist (albuterol) or 
an anticholinergic (ipratropium bromide) can be used in 
this setting with the final choice reflecting patient response, 
preference, and medication availability. Combination short-
acting bronchodilator therapy appears to provide additional 
benefit in FEV1 response.25
Symptomatic patients with moderate to very severe COPD 
should be treated with one or more long-acting bronchodilators 
in addition to short-acting as-needed rescue inhaler(s).15 Of note, 
a detailed history may be required to identify “symptomatic” 
patients, since many people with COPD slowly reduce their 
activity level and attribute their symptoms to “natural aging.” 
Options for treatment with long-acting bronchodilators include 
the long-acting beta 2-agonists (LABA) salmeterol, formoterol, 
or arformoterol and the long-acting anticholinergic (LAAC) 
tiotropium. These long-acting bronchodilator agents have been 
shown to significantly improve lung function, quality of life, and 
reduce hyperinflation.15,26–28 There are no recommendations for 
which agent to start initially, but it is clear that long-acting bron-Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
184
Sonetti et al
chodilators are superior and more effective, albeit also more 
expensive, than short-acting bronchodilators.15 One landmark 
trial (entitled Understanding Potential of Long-term Impacts on 
Function with Tiotropium [UPLIFT]) of nearly 6,000 subjects 
with COPD followed for 4 years   evaluated tiotropium compared 
with placebo.27 Both groups also received “usual care,” which 
included a LABA and/or inhaled corticosteroid therapy (ICS) 
in over 60% of subjects. The study did not achieve its primary 
end point of demonstrating a change in the rate of decline of 
FEV1. However, the tiotropium group had a sustained increase 
in lung function, a reduction in AECOPD, improved quality of 
life, and reduced cardiac morbidity.27
The GOLD guidelines recommend the addition of ICS 
to long-acting bronchodilator therapy only in patients with 
severe COPD and in those with repeated exacerbations.15 
The ideal combination of bronchodilator and inhaled steroid 
therapy is not known. Another landmark study of over 6,000 
subjects followed for 3 years (entitled TOwards a Revolu-
tion in COPD Health [TORCH]) evaluated the combination 
LABA and ICS (salmeterol/fluticasone), compared with 
each individual agent and placebo. This study also did not 
reach its primary end point of a reduction in mortality, with 
a P value of 0.052. However, it is thought that the actual 
effect on   mortality may be underestimated due to the loss of 
sicker patients in the placebo group who dropped out of the 
study seeking active treatment. Similar to the improvements 
in the treatment group of the UPLIFT trial, the TORCH trial 
demonstrated a significant reduction in the frequency of exac-
erbations and improvement in quality of life and lung function 
in subjects treated with salmeterol/fluticasone   combination 
therapy.28 Triple therapy with LABA, LAAC, and ICS has 
been shown to improve quality of life, lung   function, and 
health care use when compared with LAAC alone or LAAC in 
combination with ICS.29 In contrast to the known benefits of 
these maintenance inhaled medications, the GOLD guidelines 
clearly state that there is no role for long-term oral gluco-
corticosteroids in COPD due to lack of significant benefits 
and the potential for serious side effects including cataracts, 
osteoporosis, and myopathy.15 In patients with severe COPD, 
steroid myopathy has been shown to decrease functionality 
and increase the risk of respiratory failure.30
Mucolytic therapy has been used for many years in an 
attempt to reduce sputum tenacity in patients with COPD 
despite controversy on whether changes in mucus viscosity 
alter cough effectiveness.31,32 In one of the best studies to date, 
a large randomized placebo-controlled trial of   N-acetylcysteine 
(NAC), no benefit in prevention of deterioration in lung func-
tion or prevention of exacerbations was seen.33 Subgroup 
analysis, however, suggested a decreased exacerbation rate in 
patients receiving NAC but not treated with ICS. A subsequent 
Cochrane meta-analysis which included this study and 27 other 
randomized controlled   trials evaluating a variety of drugs 
concluded that mucolytic therapy was associated with a small 
reduction in the rate of acute exacerbations.34 According to the 
GOLD guidelines, “the overall benefits seem to be very small 
and widespread use of these agents cannot be recommended 
at present”.15 It is also important to note that coughing serves 
to clear the airways of mucus due to excessive secretions or 
impaired mucociliary clearance and that suppression of this 
natural and protective reflex with antitussive therapy should 
generally be avoided in patients with COPD.35
A number of nonpharmacologic treatments for patients with 
COPD also improve outcomes, including pulmonary rehabilita-
tion, supplemental oxygen in selected patients, vaccinations, 
and surgery. Pulmonary rehabilitation focuses on exercise con-
ditioning, breathing retraining, psychosocial support, smoking 
cessation, and nutritional   counseling.36 Pulmonary rehabilitation 
programs have recently seen tremendous growth in interest as 
additional supporting clinical data now clearly demonstrate 
reduced dyspnea, increased exercise tolerance, improved 
physical and emotional participation, and decreased health care 
costs.37 The mechanism of action is multifaceted and includes 
(1) improved muscle function with less metabolic demand for 
a given intensity level, (2) lower ventilatory demand which 
serves to reduce dynamic hyperinflation, (3) desensitization 
to dyspnea through exertion and possible antidepressant effect 
of exercise, and (4)   education focused on self-management 
strategies.38 Pulmonary rehabilitation is recommended for 
patients with moderate to very severe COPD.15 One therapy 
for COPD that has been shown to decrease mortality is oxygen 
therapy for patients with hypoxemia at rest. In patients with 
COPD and resting hypoxemia, defined as a PaO2 # 60 mm Hg 
and rarely manifests as cold extremities secondary to hypoxic 
peripheral vasoconstriction, oxygen therapy of two L/min for at 
least 15 hours daily was associated with a mortality benefit for 
five years of over 20%.39 Medicare guidelines include continuous 
oxygen therapy for patients with a resting PaO2 # 55 mm Hg 
or saturation of #88%. In patients with exertional hypoxemia, 
ambulatory oxygen therapy may improve six-minute walk per-
formance and dyspnea but it has not been shown to decrease 
mortality.40 Influenza vaccination has been shown to prevent 
acute respiratory infections in patients with all severities of 
COPD.41 In severe cases, a selected group of patients with pre-
dominantly upper-lobe emphysema and low exercise capacity 
have improved functional status and a survival advantage after 
lung volume reduction surgery.42 Lung transplantation may also Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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be considered in patients with severely symptomatic COPD to 
improve quality of life.43 Referral to an expert in COPD man-
agement is strongly encouraged if surgical   treatment options 
are considered.
Ensuring proper inhaler technique should not be over-
looked as a way to improve outcomes in patients with COPD. 
Up to 54% of patients have been found to use poor aerosol 
inhalation technique, a deficiency that can be improved with 
appropriate training.44,45 Fundamentally, metered dose inhalers 
require a deep, slow inhalation and substantial hand – mouth 
coordination. Difficulties with coordinating actuation and 
inhalation are the most commonly reported problems with 
metered dose inhalers, but they can easily be overcome with 
the use of a spacer device.46 Dry-powder inhalers, in contrast, 
require a deep forceful inhalation for effective medication 
delivery. Metered dose inhalers with spacers, dry-powder 
inhalers, and nebulizers are all equally effective at drug 
delivery for most patients when used correctly.47 Provid-
ing appropriate inhaler instructions and observing patients 
demonstrate that their technique at follow-up clinic visits 
are keys to assuring patients receive their prescribed doses of 
medicines. One free online resource for patient educational 
handouts in English, Spanish, and large print on the variety of 
inhalers can be found at the American College of Chest Physi-
cians website (http://www.chestnet.org/accp/patient-guides/
patient-instructions-inhaled-devices-  english-and-spanish).
Management of comorbidities
COPD is a systemic disease with many associated comorbidi-
ties that often carry greater morbidity and mortality risk than 
the lung disease itself. One significant class of comorbidities 
to consider are the psychiatric effects of COPD, which include 
anxiety, panic attacks, sleep disturbances, and depression.48–50 
The rates of depression and/or anxiety among COPD patients 
vary from 20% to 65% and increase with acute exacerba-
tions and as the severity of obstruction increases.48,51 These 
comorbidities have a significant negative effect on patient 
quality of life, functional status, and life-sustaining treat-
ment preferences. Unfortunately, these comorbidities remain 
undetected, unrecognized, and untreated by clinicians in the 
majority of patients with COPD.48,50,52
There is little evidence evaluating the efficacy of 
antidepressant and anxiolytic therapy in COPD. In one 
small, randomized, placebo-controlled trial, the tricyclic 
antidepressant nortriptyline was shown to significantly 
improve short-term outcomes for depression, anxiety, 
distressing physical   symptoms (e.g., feeling easily exhausted 
or suffocated), and overall disability.53 In a study of cognitive 
behavioral therapy (CBT), a single intensive two-hour session 
resulted in a   significant improvement in depressive and anxi-
ety symptoms relative to education only.54 In another study 
comparing CBT with education alone, significant improve-
ments in symptoms were seen in both groups after an 8-week 
intervention and during subsequent follow up.55 Although 
pharmacologic therapy with tricyclic antidepressants has 
been proven effective in patients with COPD, newer medi-
cations with improved side effect profiles such as selective 
serotonin reuptake inhibitors (SSRIs) have become the pre-
ferred agents. Preliminary data from a small prospective trial 
suggests that 3 months of SSRI therapy decreases symptoms 
of depression while improving walking distance and degree 
of breathlessness.56 At our institution, buspirone has been par-
ticularly effective for the treatment of COPD-related anxiety. 
Doses can be rapidly titrated up to a typical maintenance of 
10–20 mg 3 times daily with minimal risk of serotenergic 
syndrome symptoms and abrupt cessation of buspirone does 
not carry risk of withdrawal. Benzodiazepines can also be 
effective but they should be used cautiously and only at low 
doses in patients with preexisting hypercapnia.57
Sleep disorders in patients with COPD, especially in 
those with moderate to severe disease, are common and 
include insomnia, obstructive sleep apnea (OSA), and rest-
less legs syndrome (RLS).58,59 Sleep-maintenance insomnia, 
in particular, can be attributed to frequent awakenings from 
coughing, wheezing, and dyspnea. In one study, asymptom-
atic COPD patients were noted to have significantly less 
insomnia than those with symptoms.60 Optimizing COPD 
therapy is paramount to treat insomnia in this population.59 
Sleep produces mild detrimental effects on normal respira-
tory function which are accentuated in those with COPD. 
Ten to 20% of COPD patients suffer from OSA and the 
coexistence of these conditions is recognized as the Over-
lap Syndrome.60,61 More pronounced daytime hypercapnia, 
nocturnal hypoxemia, and pulmonary hypertension are 
present in Overlap Syndrome patients than in those with 
either disease alone.60,61 Optimization of COPD medica-
tions, supplemental oxygen therapy, and continuous posi-
tive airway pressure (CPAP) are the mainstays of treatment 
for this condition. Supplemental oxygen therapy has been 
shown to improve nocturnal hypoxemia and significantly 
impact the course of pulmonary hypertension, although its 
effect on sleep quality has yet to be proven.60 Commonly, 
this group of patients will require CPAP, with or without 
supplemental oxygen. According to the American Academy 
of Sleep Medicine, patients with COPD are not candidates 
for autotitrating CPAP devices.62 Rather, CPAP therapy at Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
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a set pressure determined by attended polysomnography 
is the current   recommendation. CPAP has been shown to 
improve gas exchange, lung   function, and respiratory muscle 
function in those with COPD and OSA, as well as enhance 
sleep quality.60,63 A recent study indicates a positive effect of 
CPAP therapy on survival of patients with moderate to severe 
Overlap Syndrome.63 Finally, there is an increased prevalence 
of RLS symptoms in COPD; however, the pathophysiologic 
mechanism remains unclear.64 COPD patients respond to 
standard dopamine agonist therapy for this condition.
Other nonpulmonary issues that affect patients with 
COPD include severe malnutrition and osteoporosis. 
Pulmonary cachexia, defined as weight loss secondary to 
severe pulmonary disease, affects up to 35% of patients with 
moderate to very severe COPD and is an independent pre-
dictor of mortality.65 Contributing factors include a chronic 
hypermetabolic state due to the increased work of breathing, 
tissue hypoxia, and anorexia. Nutritional supplementation 
has not been shown to improve outcomes alone, but when 
combined with dietary counseling patients report improve-
ments in quality of life, dyspnea, and functional status.66,67 
Resting prior to meals and eating small more frequent meals 
can also improve caloric intake. Osteoporosis affects up to 
35% of COPD patients.68 Correlates of this disease include 
low body mass index, low FEV1, and prior corticosteroid 
exposure. Treatment follows standard recommendations with 
bisphosphonates and calcium with vitamin D.
Conclusion
Reflecting back to our clinical encounter with Mrs B, a 56-year-old 
female with a long history of tobacco use who was recently 
diagnosed with severe COPD after experiencing recurrent epi-
sodes of shortness of breath resulting in   hospitalization. Mrs B 
also reported complaints of cold hands and insomnia and her 
husband was concerned that she had become withdrawn. As 
you may recall, she ascribed her shortness of breath to advanc-
ing age, which consequently delayed her initial presentation to 
the medical community. During her clinic visit, supplemental 
oxygen was started for her resting hypoxia and within minutes 
she reported that her hands had finally warmed, reflecting the 
correction of the rarely seen peripheral vasoconstriction sec-
ondary to chronic hypoxemia. Arrangements for continuous 
home oxygen therapy were made and she was counseled on 
the importance of   wearing oxygen at least 15 hours per day. 
When Mrs B was asked about her willingness to stop   smoking, 
she stated that she was motivated, but had been trying without 
success to stop smoking. She reported that she did not want 
smoking cessation counseling, but was willing to receive 
pharmacological help to achieve   smoking   abstinence. Due to 
the severity of her COPD (severe by GOLD guidelines) and 
history of multiple exacerbations, the patient was also started 
on “triple inhaler therapy” with a LAAC and a LABA in com-
bination with an ICS. A spacer device was also provided to be 
used with her short-acting albuterol. She was instructed by the 
medical assistant on the proper inhaler technique for all devices 
and was provided with the patient instructions complete with 
color pictures from the American College of Chest Physicians 
website. She agreed to enroll in an 8-week comprehensive 
pulmonary rehabilitation program, which included exercise 
training, nutrition counseling, psychological support, and 
self-management education and then continued to participate 
in a maintenance program. Finally, she was evaluated by a 
sleep doctor, underwent polysomnogram, and was started 
on CPAP for moderate OSA. Upon initial follow up with her 
case manager, the patient reported getting out of the house 
more for shopping and dining thanks to reduced symptoms 
of dyspnea and improved mood. She also reported improved 
sleep and her husband believes she is more energetic. At her 
2-month follow-up visit, Mrs B admitted to restarting smoking 
after stopping for only 1 week, but that she now smoked only 
about one half of her previous amount. After discussing and 
addressing some of the reasons that she started smoking again, 
she stated that she was willing to try again, this time with the 
help of a smoking cessation counselor. Her influenza vaccine 
was updated thanks to an electronic medical record reminder, 
effective inhaler technique was reviewed, and a bone mineral 
density scan was ordered to evaluate for possible osteopenia 
seen on chest X-ray. In addition, she was further counseled 
on the importance of using her CPAP all night, every night, 
and during naps. Mrs B had regular contact with her case 
manager and access to a 24-hour clinic hotline, but she has 
not yet needed to use the hotline, nearly 6 months after her 
initial clinic visit.
In summary, COPD is a multisystem disease with signifi-
cant morbidity and mortality that remains underdiagnosed 
and undertreated. We have reviewed the evidence-based 
guidelines for managing this disease including smoking 
cessation, long-acting bronchodilator therapy, pulmonary 
rehabilitation, and long-term oxygen therapy for patients 
with resting hypoxemia. We have also highlighted the 
  importance of the most common comorbid diseases like 
anxiety, depression, sleep disorders, pulmonary cachexia, 
and osteoporosis. The complexity of managing COPD and its 
multiple comorbidities is best addressed with a multifaceted 
team of providers. The CCM provides the framework for this 
type of approach by fostering productive interactions between Journal of Multidisciplinary Healthcare 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
187
integrated care for COPD
informed patients who actively participate in their care and 
experienced providers who rely both on community resources 
to provide patient specific education and on technology to 
ensure compliance with evidence-based treatment guidelines. 
Successful   employment of the CCM shifts the focus from 
acute management of   complications to one of the prevention 
and is an effective way to improve COPD outcomes.
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